Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Total Non-Current Liabilities (2021 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Total Non-Current Liabilities for 5 consecutive years, with $9.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 40.08% to $9.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $9.8 million, a 40.08% decrease, with the full-year FY2024 number at $17.6 million, down 35.22% from a year prior.
  • Total Non-Current Liabilities was $9.8 million for Q3 2025 at Whitehawk Therapeutics, up from $8.8 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $27.2 million in Q4 2023 to a low of $8.8 million in Q2 2025.
  • A 5-year average of $16.7 million and a median of $17.0 million in 2024 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: plummeted 35.22% in 2024, then tumbled 40.08% in 2025.
  • Whitehawk Therapeutics' Total Non-Current Liabilities stood at $21.5 million in 2021, then decreased by 7.94% to $19.8 million in 2022, then surged by 37.54% to $27.2 million in 2023, then crashed by 35.22% to $17.6 million in 2024, then crashed by 44.16% to $9.8 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Total Non-Current Liabilities are $9.8 million (Q3 2025), $8.8 million (Q2 2025), and $12.3 million (Q1 2025).